CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity ...

Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) says a recent financing round has extended its cash runway into 2026, providing time for the clinical-stage biopharmaceutical company to work ...

New York startup Abeona Therapeutics just raised $8.5 million to expand its gene therapy pipeline for rare disease like Sanfilippo syndrome, juvenile Batten disease and Fanconi anemia. Notably, the ...

Abeona Therapeutics is at a critical juncture, trading near 52-week lows ahead of its first ZEVASKYN revenue update in Q3. ZEVASKYN, a one-time gene therapy for severe skin disorder, faces execution ...

Gene and cell therapy company Abeona Therapeutics Inc. (Nasdaq: ABEO), which is co-headquartered in Cleveland and New York, said it has promoted Michael Amoroso, senior vice president and chief ...

Abeona Therapeutics announced it is just weeks away from enrolling the first patients in a trial of its gene therapy for the lysosomal storage disease Sanfilippo B. The new comes as the gene therapy ...

Abeona Therapeutics has overcome an FDA clinical hold to show that its cell therapy can heal wounds in patients with a rare connective tissue disease, teeing up an FDA filing in the new year. Back in ...

The Food and Drug Administration has rejected an experimental cell therapy for a rare skin condition, asking its developer, Abeona Therapeutics, to provide more information about how the treatment is ...

Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after an ...

A clinical trial update for AB-102 didn't go far enough. With shares having more than tripled over the past year, it may be more what Abeona didn't say in its update than what it did say that caused ...

Management reaffirmed the goal to treat 10–14 ZEVASKYN patients in 2025, with a robust start for 2026 anticipated. Vasanthavada explained the expectation for a gradual ramp-up at QTCs, with greater ...